Immunohistochemical predictors in squamous cell carcinoma of the tongue and floor of the mouth

Abstract

It seems that targeting MMP-2 and VEGF-C may improve local control, thereby reducing the risk of distant metastasis in patients with SCC of the tongue and FOM. © 2015 Wiley Periodicals, Inc. Head Neck 38: E747-E753, 2016.

Association between immunohistochemical expression of matrix metalloproteinases and metastasis in oral squamous cell carcinoma: Systematic review and meta‐analysis

“…Of these, 118 full‐text studies were assessed, of which 68 did not meet the inclusion criteria (Appendix 2). Therefore, 50 analytical cross‐sectional studies were included in the qualitative synthesis and 15 in the quantitative synthesis (Figure ).…”

“…All studies reported the association between MMPs expression and LNM, of which nine did not present crude data, and one performed an adjusted analysis for confounding factors, although the variables used in the multivariate analysis were not stated . In addition, only four studies reported data on the association of MMPs expression with DM …”

“…Percentage of positive cells was the most used method, with further categorization using different cutoff values. Analyses were performed in tumor cells alone (tumor), tumor and stromal cells separately (tumor/stroma), and tumor and stroma simultaneously (tumor+stroma) . Detailed information regarding the main features, and findings of the included studies are presented in Table .…”

“…MMPs are expressed in almost all types of cancer and are associated with tumor progression and invasion . Among others, MMP‐2 and ‐9 are the most prominent, being responsible for basement membrane breakdown; thus, their association with cancer is extensively reported in the literature . Previous systematic reviews (SR) have associated the presence of MMPs ‐7, ‐2, and ‐9 with poor disease outcomes in different types of cancers, such as breast and lung carcinoma …”

MMP2 As An Independent Prognostic Stratifier In Oral Cavity Cancers

“…Several studies have proposed MMP2 as a prognostic biomarker for OCSCC, but all had important limitations, such as the absence of multivariate analysis (21), (22), (23), the inclusion of heterogeneous head and neck cancer patients with different tumor locations and treatments (24), (25), or retrospective cohorts with less than 60 patients (22), (23), (26), (27). Most of these studies quantified MMP2 by immunohistochemistry (IHC) through semi-quantitative methods.…”